The use of Botox (BTX-A) as a safe, reversible, and effective treatment for reducing muscle tone and improving gait in children with cerebral palsy.
Incobotulinumtoxin A is under clinical development by Merz Therapeutics and currently in Phase II for Unspecified Musculoskeletal Disorders.
Onabotulinumtoxin A is under clinical development by AbbVie and currently in Phase III for Unspecified Musculoskeletal Disorders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback